Pharmacist Yomna Nassar

Bild Yomna Nassar

Institute of Pharmacy

Clinical Pharmacy & Biochemistry

Address
Kelchstr. 31
Room 130 A
12169 Berlin
Email
yomna.nassar[at]fu-berlin.de

Curriculum Vitae

7/2019-Present

Doctoral student at the Graduate Research Training Program “PharMetrX: Pharmacometrics & Computational Disease Modelling“ at the Dept. of Clinical Pharmacy & Biochemistry supervised by Prof. Dr. Charlotte Kloft at the Freie Universitaet Berlin

9/2013-6/2019

Pharmacist specialist at the Department of Pharmacology-Medical Research Division

National Research Centre, Giza, Egypt

2/2012-6/2019

Senior Clinical Research Associate

Pharmagene Specialized Analytical Services; a CRO focusing on bioequivalence studies, pharmacokinetic studies and bioanalysis

9/2016-9/2017

Visiting Master student

UCL Great Ormond Street Institute of Child Health, London, UK

2015-2017

MSc in Experimental Therapeutics

Kellogg College, University of Oxford, Oxfordshire, UK

Dissertation title: Pharmacometrics of treosulfan in children undergoing haematopoeitic stem cell transplantation

2006-2011

Bachelor degree of Pharmaceutical Sciences

Faculty of Pharmacy-Ain Shams University, Cairo, Egypt

2006

General Certificate of Secondary Education (Science section)

Ramses College for Girls, Cairo, Egypt

Optimising dosing strategy of paclitaxel in NSCLC

 

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. Paclitaxel, a taxane derived chemotherapeutic agent, in combination with platinum containing drugs (e.g. cisplatin or carboplatin) have been routinely used as a first-line treatment in patients with advanced NSCLC. Nevertheless, successful treatment is often hindered by dose-limiting toxicities such as neutropaenia and neurotoxicity. Therefore, it is important to have tolerable paclitaxel concentrations that do not hinder treatment efficacy and at the same time maintain a tolerable toxicity profile.

To achieve this, the timely prediction of treatment outcome (e.g. tumour response to treatment, overall survival,… ) is needed. Therefore, time course pharmacokinetic/pharmacodynamics models of prognostic treatment markers (i.e. biomarkers) will be developed and relevant metrics that best predict treatment response will be evaluated. These efficacy models will then be combined with other toxicity models of neurotoxicity and haematotoxicity to evaluate the clinical utility of paclitaxel-based treatment. This joint description of the risk of toxicity and efficacy will help identify more ideal dosing schedules that can minimise incidence and severity of relevant toxicities and simultaneously retain clinical efficacy.

I hope that with this work, the timely identification/prediction of disease progression/regression would consequently prompt favourable interventions to avoid unnecessary side effects or ineffective treatment and that evaluating the risk of dose-limiting, treatment-related toxicities in relation to treatment efficacy would eventually identify safe and effective dosing schedules.